<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446264</url>
  </required_header>
  <id_info>
    <org_study_id>CP 01/48</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <secondary_id>AFSSAPS 030209</secondary_id>
    <nct_id>NCT00446264</nct_id>
  </id_info>
  <brief_title>Islet Allotransplantation With Steroid Free Immunosuppression</brief_title>
  <official_title>Sequential Islet Transplantation With Steroid Free Immunosuppression for Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The restoration of endogenous insulin secretion carries significant hopes for shifting the
      paradigm of life long exogenous insulin therapy in selected groups of patients with type 1
      diabetes(T1D). After decades of frustrating clinical attempts, the Edmonton group set up in
      2000 new standards for islet transplantation in patients with brittle T1D by achieving
      insulin independence in 80 percent of patients. These seminal results have however proved
      much more difficult to duplicate than initially expected.

      This single center phase 2 clinical trial, duplicating the Edmonton protocol, is designed for
      confirming the consistent short term efficacy and safety of sequential islet
      allotransplantation with steroid free immunosuppression in patients with severe T1D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The short term effectiveness of islet transplantation for alleviating hypoglycemia and
      controlling glucose homeostasis while limiting or even avoiding the nedd for exogenous
      insulin has been established despite protocol modifications in donor selection, islet
      preparation or recipient treatment, insulin independence with adequate metabolic control was
      however rarely prolonged beyond two years. The most frequently proposed explanations include
      chronic allogenic rejection, recurrence of autoimmunity and beta cell toxicity from
      administered immunosuppressive drugs.

      Fourteen patients were enrolled in this single center phase 2 trial initiated in 2003.
      Eligible patients were males or females between 18 and 65 years of age, with type 1 diabeted
      documented for more than 5 years, arginine stimulated C-peptide lower than 0.2ng/ml, and
      hypoglycemia awareness or documented metabolic lability. Exclusion criteria included body
      mass index greater than 28Kg/m2, unstable arteriopathy or heart disease, active infection,
      previous transplantation, insulin daily requirements above 1.2 UI/kg, creatinin clearance
      below 60 ml/mn/m2 or urinary albumin excretion above 300 mg/day, malignancy, smoking, desire
      for pregnancy, psychiatric disorders and lack of compliance. The study primary efficacy
      endpoint was graft survival defined as insulin independence and HbA1c&lt;6.5%. Secondary
      outcomes were graft function and metabolic control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of insulin independents subjects with an HbA1c less than 6.5% at one year after last transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events</measure>
    <time_frame>day 0 to day 365</time_frame>
    <description>Percentage of subjects free of severe hypoglycemic events from day 0 to day 365 with the day of transplant designated day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C-peptide</measure>
    <time_frame>1 year</time_frame>
    <description>Level of plasma C-peptide at 1 year after the first transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt; 6.5%</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of subjects with HbA1c &lt; 6.5% at 1 year after the first transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in Hypoglycemia (&lt;0.70 mg/L)</measure>
    <time_frame>1 year</time_frame>
    <description>percentage of time spent in hypoglycemia derived from CGMS (Continuous Glucose Monitoring System)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>The number of adverse events related to the procedure and to the immunosuppression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <condition>Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant received up to three sequential fresh islet infusions within three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>islet transplantation</intervention_name>
    <description>Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.</description>
    <arm_group_label>islet transplantation</arm_group_label>
    <other_name>surgical catheterisation</other_name>
    <other_name>percutaneous catheterisation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daclizumab - sirolimus - tacrolimus</intervention_name>
    <description>Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion</description>
    <arm_group_label>islet transplantation</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Zenapax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes documented for more than 5 years

          -  arginine stimulated C-peptide lower than 0.2 ng/mL

          -  one of the following:hypoglycemia unawareness OR metabolic lability documented by one
             or more severe hypoglycemias or two or more hospital admissions for ketoacidosis
             within the previous year.

        Exclusion Criteria:

          -  body mass index greater than 28 kg/m2

          -  non stable arteriopathy or heart disease

          -  active infection

          -  previous transplantation

          -  hyperimmunization

          -  insulin daily needs above 1.2 U/Kg

          -  creatinine clearance below 60 ml/mn or urinary albumin excretion above 300 mg/d

          -  malignancy

          -  smoking

          -  desire for pregnancy

          -  psychiatric disorders

          -  lack of compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Pattou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Christine Vantyghem, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Kerr-Conte, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Lille 2</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2007</study_first_submitted>
  <study_first_submitted_qc>March 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2007</study_first_posted>
  <results_first_submitted>May 18, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2010</results_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 2003-2006 University Lille Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm Group</title>
          <description>Islet Allotransplantation Group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Group</title>
          <description>Islet Allotransplantation Group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>18-65</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year</title>
        <description>The percentage of insulin independents subjects with an HbA1c less than 6.5% at one year after last transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year</title>
          <description>The percentage of insulin independents subjects with an HbA1c less than 6.5% at one year after last transplant</description>
          <units>Percentage of patients</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events</title>
        <description>Percentage of subjects free of severe hypoglycemic events from day 0 to day 365 with the day of transplant designated day 0</description>
        <time_frame>day 0 to day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events</title>
          <description>Percentage of subjects free of severe hypoglycemic events from day 0 to day 365 with the day of transplant designated day 0</description>
          <units>Percentage of patients</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma C-peptide</title>
        <description>Level of plasma C-peptide at 1 year after the first transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma C-peptide</title>
          <description>Level of plasma C-peptide at 1 year after the first transplant</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c &lt; 6.5%</title>
        <description>The percentage of subjects with HbA1c &lt; 6.5% at 1 year after the first transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c &lt; 6.5%</title>
          <description>The percentage of subjects with HbA1c &lt; 6.5% at 1 year after the first transplant</description>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in Hypoglycemia (&lt;0.70 mg/L)</title>
        <description>percentage of time spent in hypoglycemia derived from CGMS (Continuous Glucose Monitoring System)</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Hypoglycemia (&lt;0.70 mg/L)</title>
          <description>percentage of time spent in hypoglycemia derived from CGMS (Continuous Glucose Monitoring System)</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>The number of adverse events related to the procedure and to the immunosuppression</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Group</title>
            <description>Islet Allotransplantation Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>The number of adverse events related to the procedure and to the immunosuppression</description>
          <units>number events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Group</title>
          <description>Islet Allotransplantation Group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>cholestasis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>choleperitonitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increase of SGPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>hemocholecyst</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increase of creatinin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>oral ulcerations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>leg edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>dermatosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Violeta Raverdy</name_or_title>
      <organization>University of Lille</organization>
      <phone>00 33 3 20 62 34 30</phone>
      <email>vraverdi@univ-lille2.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

